A number of biotechs and academic researchers are investigating ways to fight drug-resistant pathogens, but Vedanta Biosciences Inc. is working to advance a novel approach toward clinical development – bringing balance back to a patient’s microbiome and using “good” gut bacteria to neutralize bad bacteria and stave off infections in at-risk patients.
Heading up this effort at the Cambridge, MA-headquartered firm is Silvia Caballero, leader of a five-person team focused on multi-drug-resistant...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?